The case and the decision

Longstanding cortisol elevation occurs without the expected catabolic features, alongside androgen and mineralocorticoid findings and a preserved nocturnal nadir. A small pituitary focus is stable. Inferior petrosal sinus sampling was performed while metyrapone had normalised cortisol measurements.

The common insight

Both tools recognise that the proposed localisation cannot be interpreted apart from the treated hormonal state. Both raise primary generalised glucocorticoid resistance rather than treating a pituitary gradient as sufficient proof of a surgical tumour.

A published NR3C1 functional case illustrates that glucocorticoid resistance can mimic pituitary Cushing disease. Separately, an IPSS case during a cyclic cortisol trough falsely suggested a pituitary source. The latter supports attention to sampling state; it was not an experiment in metyrapone-treated Chrousos syndrome. [1] [2]

How the descriptions differ

OpenEvidence leads directly with why the IPSS result should not commit the patient to surgery. That is a strong decision-focused opening. MontMedical explicitly describes the resistance diagnosis as provisional pending NR3C1 confirmation and organises the supporting findings separately from the limits.

What this pair establishes

This is substantial diagnostic agreement, not evidence that OpenEvidence failed. The unresolved questions are the molecular/functional basis of the resistance hypothesis and the meaning of sampling under the documented treatment conditions. Neither a procedural drug-withdrawal timetable nor a universal repeat-sampling rule follows from these two papers alone.